Key result
Low-dose colchicine lowers cardiovascular events compared to placebo in chronic coronary disease.
Why the study?
Does colchicine 0.5 mg once daily reduce cardiovascular events in patients with chronic coronary disease?
Does colchicine 0.5 mg once daily reduce cardiovascular events in patients with chronic coronary disease?
Answers are grounded in this paper and cite their sources.
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“These 5,000 patients were randomized either to low-dose colchicine, at a dose of 0.5 milligrams daily, or a placebo. And they were followed out for 28 months. And what the study showed was those patients randomized to 0.5 milligrams of colchicine had a 31 percent relative risk reduction in a composite of cardiovascular death, stroke, MI, and ischemia-driven coronary revascularization.”
“With 84% of patients having a prior history of acute coronary syndrome at least 6 months prior to enrolment, and the event rate being driven by ischaemia-related revascularisation, the magnitude of benefit in lower risk populations remains unclear. Finally, a higher, albeit non-significant, incidence of non-cardiovascular-related mortality was observed in the colchicine group. This merits further investigation.”
“The two clinical trials we have in front of us, the COLCOT trial and the LoDoCo2 trial– both New England Journal of Medicine papers, both with roughly 5,000 patients – provide very clear evidence that following a relatively recent myocardial infarction (that's COLCOT) in chronic stable atherosclerosis (that's LoDoCo2), we're getting 25%-30% relative risk reductions in major adverse cardiovascular events (MACEs) on top of aggressive statin therapy. That's a big deal. It's safe, it works, and it's fully consistent with all the information we have about inflammation being part and parcel of atherosclerosis.”
Low-dose colchicine (0.5 mg once daily) significantly reduces the risk of cardiovascular events compared to placebo in patients with chronic coronary disease.
In a randomized trial involving patients with chronic coronary disease, the risk of cardiovascular events was significantly lower among those who received 0.5 mg of colchicine once daily than among those who received placebo. (Funded by the National Health Medical Research Council of Australia and others; LoDoCo2 Australian New Zealand Clinical Trials Registry number, ACTRN12614000093684.).
Journal, society, and media accounts. Useful signal, not independent expert judgment.
No takes yet. Share an insight, caveat, or question.
Nidorf et al. (2020) studied this question. Colchicine lowered the risk of cardiovascular events compared to placebo in patients with chronic coronary disease.
Synapse has enriched 10 related papers. Consider them for comparative context: